NEW YORK, Jan. 03, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Universal Health Services, Inc. (“Universal Health” or the “Company”) (NYSE:UHS) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Universal Health securities from February 26, 2015 through December 7, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/uhs.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Universal Health admitted patients based on its own financial considerations and not the patient’s medical needs; (2) Universal Health would keep patients admitted until their insurance payments ran out in order to bill for the maximum of its services; (3) accordingly, Universal Health’s revenues from inpatient care relied on unjustifiable practices; (4) due to the aforementioned, Universal Health lacked efficient internal control regarding its practices and policies of admitting patients; and (5) consequently, Universal Health’s public statements were materially false and misleading at all relevant times.
On December 7, 2016 BuzzFeed released its investigation into Universal Health “…based on interviews with 175 current and former UHS staff, including 18 executives who ran UHS hospitals; more than 120 additional interviews with patients, government investigators, and other experts; and a cache of internal documents.” BuzzFeed reported that “[c]urrent and former employees from at least 10 UHS hospitals in nine states said they were under pressure to fill beds by almost any method – which sometimes meant exaggerating people’s symptoms or twisting their words to make them seem suicidal – and to hold them until their insurance payments ran out.” Following this news, Universal Health stock dropped $15.01 per share or nearly 12% to close at $111.36 on December 7, 2016.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/uhs or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Universal Health you have until February 21, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Bank of America's $72.5M Epstein Settlement: What You Need to Know
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Apple Turns 50: From Garage Startup to AI Crossroads
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 



